Dr. Jabbour on Second-Generation TKIs in CML
Elias Jabbour, MD, Assistant Professor, Dept. of Leukemia, The University of Texas MD Anderson Cancer Center, on second-generation TKIs for patients with CML, a cancer that starts inside bone marrow.
Elias Jabbour, MD, Assistant Professor, Dept. of Leukemia, The University of Texas MD Anderson Cancer Center, on second-generation tyrosine-kinase inhibitors (TKIs) for patients with chronic myelogenous leukemia (CML), a cancer that starts inside bone marrow.
Taken at the 2010 ASCO Annual Meeting.
Related Videos
Related Content
